Answers are grounded in this paper and cite their sources.
OBJECTIVE: To compare the disproportionality of hypersensitivity reactions (HSRs) associated with clinically used iodinated contrast media (ICMs) for enhanced patient safety. MATERIALS AND METHODS: We analyzed ICM-related HSR reports from the FDA Adverse Event Reporting System (FAERS) database between the Q1 of 2004 and the Q4 of 2024. Disproportionality analyses were performed to evaluate ICM-related HSR reporting odds ratio and to compare reporting rates of specific HSR subtypes across age, sex, and geographical subgroups. RESULTS: Among 22,375,298 adverse event reports retrieved, 7,515 cases were identified as ICM-induced HSRs. All the studied ICMs were associated with over-reporting frequencies of HSRs, with iopromide showing the highest reporting odds ratio (ROR = 214.11, 95% confidence interval (CI) 197.07 - 232.64). Iopromide and ioversol (ROR = 104.58, 95% CI 93.31 - 117.22) were more likely associated with angioedema than other ICMs, particularly in males and the 45 - 65 age group. Iodixanol (ROR = 17.23, 95% CI 7.95 - 37.34) was associated with the largest disproportionality for severe cutaneous adverse reactions (SCARs), while iodixanol, iopamidol (ROR = 11.90, 95% CI 9.13 - 15.52), and iohexol (ROR = 9.37, 95% CI 7.65 - 11.46) were more likely associated with SCAR than other ICMs, particularly in the 45 - 65 age group. Regarding anaphylactic shock, iopamidol (ROR = 117.18, 95% CI 103.13 - 133.14) and ioversol (ROR = 83.91, 95% CI 74.68 - 133.14) presented a higher disproportionality, especially in males and seniors aged > 65 years. CONCLUSION: The disproportionality signal profiles of ICM-related HSRs vary significantly across specific agents and are influenced by age and sex.
No takes yet. Share an insight, caveat, or question.
Qiu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: